Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

Immunocore's IMC-P115C Phase 1 Trial - Immunocore has dosed the first patient in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate targeting PRAME-expressing tumors [6] - IMC-P115C is designed with the same CD3 effector and TCR specificity as brenetafusp, but with an extended half-life [6] - The Phase 1 trial will evaluate safety, pharmacokinetics, and clinical activity in HLA-A02:01-positive patients with advanced solid tumors expressing PRAME [6][7] IMC-P115C Development and Mechanism - IMC-P115C is Immunocore's first half-life extended candidate and the sixth ImmTAC candidate to enter clinical trials [2] - It is a PRAME x CD3 ImmTAC bispecific protein targeting the same HLA-A02:01 PRAME peptide as brenetafusp [2] - The trial aims to assess preliminary anti-tumor activity and pharmacokinetics of IMC-P115C [8] ImmTAC Technology Overview - Immunocore's ImmTAC molecules are bispecific biologics designed to redirect the immune system to recognize and kill cancerous cells [3] - These molecules use engineered soluble TCRs to recognize intracellular cancer antigens with ultra-high affinity and selectively kill cancer cells via an anti-CD3 immune-activating effector function [3] - The ImmTAC mechanism has potential to treat both hematologic and solid tumors, including immune "cold" low mutation rate tumors [3] Immunocore's Pipeline and Focus - Immunocore is a commercial-stage biotechnology company developing TCR bispecific immunotherapies called ImmTAX for cancer, autoimmune diseases, and infectious diseases [4] - The company has a deep pipeline with nine active clinical and pre-clinical programs across multiple therapeutic areas [9] - Its most advanced oncology TCR therapeutic, KIMMTRAK, is approved for unresectable or metastatic uveal melanoma in several regions [9] Clinical Development and Future Prospects - The Phase 1 trial of IMC-P115C builds on the largest Phase 1/2 PRAME dataset from brenetafusp, which served as the basis for the first Phase 3 trial with a PRAME therapy [7] - Immunocore aims to expand the understanding of PRAME candidates through this trial [7] - The company continues to pioneer transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases [6]